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Multiple sclerosis patients carry an 
increased burden of exceedingly 
rare genetic variants in the 
inflammasome regulatory genes
Lovro Vidmar1, Ales Maver  1, Jelena Drulović2, Juraj Sepčić3, Ivana Novaković4, 
Smiljana Ristič5, saša Šega6 & Borut peterlin1
The role of rare genetic variation and the innate immune system in the etiology of multiple sclerosis 
(MS) is being increasingly recognized. Recently, we described several rare variants in the NLRP1 gene, 
presumably conveying an increased risk for familial MS. In the present study we aimed to assess rare 
genetic variation in the inflammasome regulatory network. We performed whole exome sequencing 
of 319 probands, comprising patients with familial MS, sporadic MS and control subjects. 62 genes 
involved in the NLRP1/NLRP3 inflammasome regulation were screened for potentially pathogenic 
rare genetic variation. Aggregate mutational burden was analyzed, considering the variants’ predicted 
pathogenicity and frequency in the general population. We demonstrate an increased (p = 0.00004) 
variant burden among MS patients which was most pronounced for the exceedingly rare variants with 
high predicted pathogenicity. These variants were found in inflammasome genes (NLRP1/3, CASP1), 
genes mediating inflammasome inactivation via auto and mitophagy (RIPK2, MEFV), and genes 
involved in response to infection with DNA viruses (POLR3A, DHX58, IFIH1) and to type-1 interferons 
(TYK2, PTPRC). In conclusion, we present new evidence supporting the importance of rare genetic 
variation in the inflammasome signaling pathway and its regulation via autophagy and interferon-β to 
the etiology of Ms.
Multiple sclerosis (MS) is a debilitating neurological disease affecting young adults. While its etiology remains 
unexplained, it is considered to be an autoimmune multifactorial disease with Epstein-Barr virus (EBV) infection 
as its main environmental risk factor1. Its genetic component has been addressed with considerable effort by 
the genome wide association (GWA) studies which have identified over two hundred risk conveying common 
genetic variants, predominantly related to the immune system genes2. However, GWA studies have proven inad-
equate for the investigation of exceedingly rare, and especially idiosyncratic variants which can only be detected 
using sequencing approaches3–5. We use the term “exceedingly rare” to refer to the variants with minor allele 
frequency (MAF) below 0.0001, representing a major part of human genetic variation which is not captured by 
the SNP-array genotyping technology6. Enabled by the next generation sequencing (NGS) technology, we have 
recently reported several rare variants in the NLRP1 gene, presumably conveying an increased risk for MS in 
families with multiple affected members7.
NLR Family Pyrin Domain Containing 1 (NLRP1) functions as the pattern recognition receptor (PRR) within 
the multi-protein signaling assemblies called inflammasomes, which lay at the forefront of the innate immune 
system. Their importance extends beyond infectious disease, as deregulated inflammasome activity has been 
associated with inflammatory8, autoimmune9 and neurological10 diseases, including MS11–14. Various types of 
inflammasomes are distinguished based on the involved PRR. We focus on NLRP1/NLRP3 inflammasomes 
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which operate in a similar fashion. Canonical inflammasome activation requires a priming step which promotes 
the transcription and translation of core inflammasome proteins: NLRPs and caspase-1 (CASP1)15. Thereafter, a 
wide variety of pathogen or danger associated molecular patterns (PAMP/DAMP) recognized by the NLRPs can 
trigger their oligomerization with Apoptosis-Associated Speck-Like Protein (PYCARD) to assemble an active 
inflammasome complex able to process its main effectors, interleukin-1β (IL-1β) and IL-18, whose increased 
levels are associated with MS16,17, demyelination and blood-brain barrier breakdown18. The priming step can be 
triggered by a number of independent PRRs and is largely propagated by Nuclear Factor Kappa-B (NF-kB) and 
type-1-interferon (IFN1) responses19. To curb excessive inflammasome activation the cell employs several nega-
tive regulatory mechanisms, many of which have evolved recently and are unique to humans. These include the 
sequestration of inflammasome proteins20 and their posttranslational modifications leading to their elimination 
by autophagy21,22. Examples of crosstalk between these regulatory modalities were described recently23,24, adding 
additional complexity to the network of proteins governing inflammasome activation.
While the sequencing of extended families with multiple affected members has been successful at identifica-
tion of rare causal variants in the past, this approach is generally limited to highly penetrant variants which seg-
regate with the disease. On the other hand, association studies are required to identify novel variants with small 
to moderate effects on disease risk. To address the diminishing power that comes with increased rarity of the 
investigated variants, variants can be aggregated25 over a biologically relevant region, such as a gene or a pathway. 
The burden of these variants can be evaluated for an association with the disease as a set25, instead of testing the 
effects of individual variants, as is commonly done in GWA studies.
Based on existing evidence11–14 and our previous results7 we hypothesized that rare functional variants at 
inflammasome related loci can deregulate inflammasome function, leading to increased risk for MS. In the pres-
ent study we aggregated the NGS-discovered rare protein-altering variants over 62 genes crucial for NLRP1/
NLRP3 inflammasome regulation (Table 1) and compared their overall burden among the cohorts of MS patients 
from multiplex families (MSFAM), sporadic MS patients (MSS), and controls (CTRL). The variants’ MAF was 
obtained from the gnomAD26 database of over 140,000 sequenced individuals, and their potential for functional 
consequence on the proteins was assessed by CADD27 scoring algorithm.
The results presented in this study demonstrate an increased burden of rare protein altering variants in the 
inflammasome regulatory genes of MS probands. The excess burden is especially pronounced for variants ranking 
highest in the employed pathogenicity criteria.
Results
In the investigated inflammasome regulatory genes28 (Table 1), we detected 300 rare (MAF < 0.05) protein alter-
ing variants with total allele count of 1031. The variant loci were successfully genotyped in 99.7% of probands.
SKAT burden test29 showed both familial and sporadic MS cohorts were significantly enriched for rare variant 
burden in the analyzed gene panel compared to the control cohort (MSFAM: p = 0.00025; MSS: p = 0.00002; 
MS-combined: p = 0.00004).
In a separate analysis performed to identify a subset of variants with the most likely functional significance, 
all variants were annotated with CADD scores and MAF obtained from the gnomAD database. Variants which 
were absent from the gnomAD database were five times as common among the MS probands compared to 
the ethnically matched control cohort (Chi.sq p = 0.008). Plotting the aggregated variant burden for multiple 
MAF and CADD-score cutoffs demonstrated a trend whereby increasingly rare (Fig. 1 - panel A) and damaging 
(Fig. 1 - panel B) variants were more enriched in both MS cohorts (individually compared to the control cohort). 
To assess if this finding was specific for the investigated set of inflammasome regulatory genes (Table 1), the 
observed trends were compared to 100,000 random gene sets of the same size in a Monte Carlo simulation. The 
Essential 
inflammasome Inflammasome priming19 Regulation by sequestration28
Postranslational modification 
and auto/mitophagy28 PTPs28
NLRP1 EIF2AK2 (PKR) IRF3 HDAC6 BRCC3 NOD2 PTPN2
NLRP3 DDX58 (RIG-1) IRF7 NR1H4 MARCH7 RIPK2 PTPN6
PYCARD IFIH1 (MDA-5) TYK2 CASP8 FBXL2 SQSTM1 (P62) PTPN22
CASP1 DHX58 (LGP2) JAK1 FADD MEFV SESN2 PTPRC
TMEM173 (STING) MAVS POP1 ULK1 IL4 DUSP1
ZBP1 (DAI) STAT1 PYDC2 (POP2) TRIM31 SIRT2
POLR3A STAT2 PYDC5 (POP3) MAPK8 FLI1
CGAS TICAM1 CARD16 (PSEUDO-ICE, COP-1) ATG5 LRRFIP2
LRRFIP1 MYD88 CARD17 (INCA) BECN1
TBK1 CHUK (IKBKA) CARD18 (ICEBERG) ATG16L1
IKBKE HSP90AA188 MAP1LC3B
HSP90AB188 FOXO3
Table 1. The inflammasome regulation gene panel. Priming step genes include cytosolic DNA/RNA 
sensors and their key downstream signaling mediators19. Protein tyrosine phosphatases (PTP) act through 
phosphorylation of NLRP385 or PYCARD86 but are written in a separate column for the sake of clarity. Five PTP 
genes already associated with inflammatory disease87 were included in the panel. Common protein names are 
written in the parenthesis.
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results demonstrated that the trends observed for the selected inflammasome gene panel were significant and 
could not be explained by a cohort related dataset bias (MAF analysis: p = 0.0005; CADD analysis: p = 0.017; see 
Supplementary Fig.S1 for results of individual MS cohorts).
In addition to separately addressing the MAF and CADD criteria, an even more convincing enrichment pat-
tern was unveiled when both variant rarity and predicted pathogenicity were accounted for concurrently (Fig. 1; 
panel C). Missense variants with MAF below 1 × 10−5 (corresponds to none, one, or two variant instances in 
the gnomAD database) and CADD-score above 20 represented 10% of missense variants. These variants were 
present almost exclusively among the MS probands and are hence forth referred to as the “selected” variants 
(Table 2). Some variant types (stop-gain/loss, splice-site, and frame-shift) are known to commonly disrupt pro-
tein functionality. Interestingly, among the 20 such variants discovered, the rarest 10 were found exclusively in 
the MS probands. These variants were included among the selected variants using the same criteria, except for the 
frame-shift variants which could not be assessed by the CADD algorithm and qualified solely based on the MAF 
criterion (three variants).
We detected 17 variants present in multiple MS probands which were considered MS enriched (Table 3), given 
the over-representation of their alleles in the MS cohorts compared to their MAF reported in gnomAD database 
(Fisher exact test; p < 0.01). Using the same method, two variants whose alleles were also overrepresented in our 
control cohort were considered population specific and were not included among the MS enriched (or selected) 
set of variants. MS enriched variants with CADD-phred scores above 20 were discovered in genes RIPK2, IFIH1, 
CHUK, PTPRC, HDAC6, DUSP1, and SIRT2.
The current study replicated two variants in the NLRP1 gene (Thr670Ile and Phe274Leu) which were recently 
described in MS probands by Bernales et al.30 - a study aimed to replicate the results of our previous publica-
tion7. Considering the combined sample sizes and the rarity of the variant alleles in the gnomAD database, the 
replication was significant as by our enrichment analysis described above (also see methods – Statistical analysis 
section).
All variants discovered in this study and their variant call quality scores are available with additional annota-
tions in the Supplementary Table S1.
Discussion
In the present study we have discovered a significantly increased burden of rare protein-altering variants within 
the genes involved in inflammasome regulation among the patients with MS. The increased burden was most 
pronounced for the exceedingly rare variants with concomitantly high predicted pathogenicity estimates which 
were present in several genes and pathways with already established links to MS or its risk factors (Fig. 2).
While GWA studies have been very successful in the identification of common (MAF > 0.05) MS risk con-
veying variants, their design has proved inadequate for capturing the contribution of rare variants, mainly for 
two reasons. Firstly, the employed SNP-array genotyping technology requires each variant to be anticipated and 
is therefore unable to detect previously unknown variation. And secondly, the power of association studies focus-
ing on individual variants declines with variant rarity25. An attempt to address the former has been published 
very recently and employed the new Illumina exome arrays containing probes for rare protein altering variants6. 
Nevertheless, variants below MAF 0.0001 received negligible coverage and even with nearly 70,000 involved cases 
and controls their main results were limited to 7 moderately rare (MAF 0.002 to 0.056) newly associated MS var-
iants in six different genes. Interestingly however, two of them and one paralogue (TYK, EIF2AK2, and HDAC6) 
also contained selected variants in our study and further two (NLRP8, PRF1) are known to be important for the 
inflammasome function31, corroborating the results of our present study. Similarly, the role of rare variation in the 
inflammasome pathway and TYK gene was supported by previous MS studies employing the NGS technology32,33.
1
2
3
4
5
1e-5 1e-4 1e-3 1e-2
gnomAD_frequency [-log10]
M
S
co
ho
rt 
fre
q.
 / 
C
TR
Lc
oh
or
t f
re
q.
Cohort
msfam
mss
A
2
4
6
8
0 10 20 30
CADD-phred_score
M
S
co
ho
rt 
fre
q.
 / 
C
TR
Lc
oh
or
t f
re
q.
Cohort
msfam
mss
B
1.3-2
2-3
3-4
4-5
5-6
<10 10-20 20-30 >30
CADD-phred_score
gn
om
A
D
_f
re
qu
en
cy
 [-
lo
g1
0]
C
Figure 1. Variant burden by MAF and CADD scores. Plots (A and B) represent how the burden of variants 
in the MS cohorts (relative to the control cohort; normalized to cohort sizes) changes with different gnomAD 
MAF and CADD score cutoffs, respectively. Panel C jointly accounts for both variant attributes and displays 
the relative burden of both MS cohorts combined. Variants qualifying into the top right corner (inner dotted 
line) were found almost exclusively among the MS probands and are listed in the Table 2 (selected variants). All 
variants qualifying within the outer dotted line were 4.7 times more common among the MS probands and are 
available in the Supplementary Table S1.
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In the present study, we employed variant aggregation25 and MAF variant annotations obtained from 
GnomAD, which enabled us to study the exceedingly rare variation despite our smaller sample size. The signifi-
cant enrichment of newly discovered variants (absent in gnomAD) among the MS cohorts compared to the eth-
nically matched control cohort was supported by significant result of the SKAT burden test and the Monte Carlo 
simulation analysis. Furthermore, among the exceedingly rare variants, those also predicted to be damaging to 
the protein function showed the most pronounced enrichment (Fig. 1 – panel C).
Besides in the aggregated variant burden analysis, we also used gnomAD to assess the significance of several 
rare variants which were discovered in two or more MS probands (MS enriched variants). While we acknowledge 
that these variants do not achieve genome-wide significance levels set for associating individual variants, the 
presence of these variants in multiple MS probands does represent an additional independent criterion. We thus 
consider the selected variants which were also MS enriched (RIPK2 p.Pro194Ser and IFIH1 p.Met619Val) our best 
candidates to be confirmed as MS associated in the future studies. However, as additional affected and healthy 
members from the extended MS families were not systematically available for segregation analysis, the penetrance 
of these variants was not assessed in the present study.
Our results provide novel evidence for the importance of rare variation in the inflammasome pathway for the 
MS etiology. Similarly, the importance of exceedingly rare variation was recently demonstrated for other CNS 
diseases, such as epilepsy34 and schizophrenia35. In general, the advent of NGS revealed that exceedingly rare 
variation accounts for a major part of human genetic variation26, thus strengthening the rationale for new studies 
and approaches aimed at the investigation of their effects on multifactorial disease, including MS.
GENE hg19 P.change Var.type gAF gAC CADD MS CTRL
Selected variants
CASP1 11_104901069_A_- p.Asn205fs frameshift 4.10E-06 1 NA 1 0
CASP8 2_202131331_C_A p.Ala100Asp missense NA 0 24.4 1 0
DHX58 17_40257124_G_C p.Thr438Arg missense 4.07E-06 1 26.7 1 0
EIF2AK2 2_37336412_T_A p.Glu468Asp missense NA 0 25.4 1 0
FOXO3 6_108985199_A_G p.Asp388Gly missense 4.06E-06 1 23.3 1 0
HDAC6 X_48681075_A_G p.Thr795Ala missense NA 0 25.5 0 1
HSP90AB1 6_44220815_T_G p.Cys589Gly missense 4.08E-06 1 22.3 1 0
IFIH1* 2_163134114_T_C p.Met619Val missense 8.14E-06 2 24.4 2 0
MEFV 16_3304478_-_C p.Gln198fs frameshift NA 0 NA 1 0
NLRP1 17_5445285_T_- p.Asn864fs frameshift NA 0 NA 1 0
NLRP3 1_247588351_C_A p.Leu536Met missense NA 0 24 1 0
POLR3A 10_79741230_C_T p.Asp1283Asn missense 8.13E-06 2 35 1 0
POLR3A 10_79769710_C_T p.Arg561Gln missense 8.12E-06 2 35 1 0
POLR3A 10_79745740_G_A p.Arg998Cys missense 8.12E-06 2 25.1 1 0
POLR3A 10_79753041_T_G p.Ile901Leu missense NA 0 22.6 1 0
POLR3A 10_79770247_T_G p.Ile542Leu missense NA 0 25.2 1 0
POLR3A 10_79764601_T_C p.Gln707Arg missense 4.06E-06 1 22.6 1 0
POP1 8_99161077_C_T p.Pro582Leu missense NA 0 33 1 0
PTPN2 18_12794395_C_T p.Arg377Gln missense NA 0 27.2 1 0
PTPN22 1_114399219_G_A p.Ala144Val missense NA 0 22.1 1 0
PTPRC 1_198701436_C_T p.Pro661Leu missense 4.08E-06 1 34 1 0
PTPRC 1_198665899_C_A p.His53Gln missense NA 0 22.9 1 0
RIPK2* 8_90782096_C_T p.Pro194Ser missense NA 0 32 2 0
SIRT2 19_39371539_T_C c.748-2 A > G splice_accep NA 0 20.6 1 0
SIRT2 19_39380575_G_A p.Pro99Ser missense 4.06E-06 1 25.7 1 0
TYK2 19_10468526_C_T p.Ala794Thr missense NA 0 23.1 1 1
TYK2 19_10479064_G_A p.Ala75Val missense 8.12E-06 2 25.3 1 0
TYK2 19_10468793_C_T p.Gly733Ser missense 4.21E-06 1 25 1 0
ULK1 12_132396530_C_T p.Pro331Leu missense 8.15E-06 2 25.7 0 1
Freq.: 0.08 0.01
Table 2. Selected variants. “hg19” represents genome coordinates in a “chr_coordinate_reference-allele_
alternate-allele” form. Splice site variants have transcript information reported in the “Protein_change” column. 
“gAF” and “gAC” columns represent variant frequency and allele count reported in the GnomAD database 
and “MS” and “CTRL” columns report the absolute numbers of variant alleles in the combined MS and control 
cohorts, respectively. All selected variants were present only in the heterozygous state, both in our cohorts 
and gnomAD (if present). Variants marked with * in the gene column also fulfilled the MS enriched variants 
criteria. “Freq.” is the overall frequency of the selected variants’ alleles considering the MS-combined and control 
cohort sizes of n = 175 and n = 144, respectively. Other relevant annotations are available in the Supplementary 
Table S1.
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GENE hg19 P.change Var.type gAF gAC CADD MS CTRL
CARD18 11_105009760_C_A p.Gly18Val missense 1.63E-05 4 11.83 3 0
CHUK 10_101959733_G_A p.Pro575Leu missense 1.63E-05 4 24.4 2 0
DHX58 17_40257832_CTG_- p.Gln391del inframe_del 4.11E-06 1 NA 2 0
DUSP1 5_172197790_C_T p.Ala56Thr missense 0.022276 2192(36) 22.7 12 6
HDAC6 X_48681187_G_A p.Arg832His missense 0.023789 4046(39) 23.9 17(14) 7(4)
IFIH1 2_163134090_C_A p.Glu627* stop_gained 0.003199 786(1) 38 7 1
IL4 5_132015548_G_A p.Arg109Gln missense 7.76E-05 19 14.77 2 0
LRRFIP1 2_238671578_T_C p.Ser408Pro missense 2.44E-05 6 2.929 2 0
CGAS 6_74161604_C_T p.Gly101Arg missense 0.015178 2080(25) 8.006 11 5
NLRP1 17_5424908_C_T p.Arg1240His missense 4.47E-05 11 0.108 3 0
PTPRC 1_198718604_G_A p.Asp1000Asn missense 0.000193 47 28.5 3 1
SIRT2 19_39379770_C_T p.Arg153His missense 0.008683 2129(19) 34 9(2) 3
TBK1 12_64891037_G_C p.Glu653Gln missense 0.000254 56 18.96 2 0
TICAM1 19_4816670_G_C p.Leu574Val missense 0.000138 34 0.001 2 0
ZBP1 20_56195349_C_T p.Met1? start_lost 0.014182 3042(32) 13.4 11 4
Table 3. MS enriched variants. See Table 2 caption text for header description. Columns “gAC”, “MS”, and 
“CTRL” report the total allele count while the allele count contributed by the homozygous probands is reported 
in the brackets. Variants Pro194Ser and Met619Val in RIPK2 and IFIH1 genes fulfilled both MS enriched and 
selected variants criteria and are reported in the Table 2.
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Figure 2. Inflammasome regulatory network. The depicted genes carried variants with MAF and CADD scores 
falling within the outer dotted region in Fig. 1; panel-C. Genes carrying the selected variants (inner dotted 
region in Fig. 1; panel-C) are bolded in red. Numbers next to the gene names represent the number of MS 
enriched variants. Black, green and red arrows represent general pathways and stimulatory/inhibitory effects, 
respectively. Genes stacked together or connected with black lines form complexes or have confirmed protein-
protein interactions (in the majority of cases via the CARD protein domain)53. Genes written with red have 
already been associated with MS. The genes are organized in five groups: Interferon response, RNA polymerase 
3 and rig-like receptors (RLRs), main inflammasome genes, other genes (regulating inflammasome activity by 
sequestration or phosphorylation), and the NOD2/RIPK2 complex integrating the latter three and inducing 
the autophagy pathway. EBV – Epstein-Barr virus, PAMP/DAMP – Pathogen/Damage-associated molecular 
patterns, ROS – Reactive oxygen species, HERV – Human endogenous retroviruses, ISGs – Interferon-
stimulated genes, IFNAR – Interferon receptor.
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Our approach has identified a set of of selected exceedingly rare variants with high pathogenicity predictions 
(CADD score), which appeared in several functionally highly connected genes, suggesting the importance of 
molecular mechanisms linking EBV, interferon-β signaling, and autophagy to the etiology of MS (Fig. 2). The 
highest burden of selected variants was discovered in the active subunit of RNA polymerase III (POLR3A), despite 
the gene being underrepresented with missense variation in the general population26. The activity of POLR3 
has been demonstrated as crucial for the immune response against the EBV and other DNA viruses36. Its func-
tion is mediated by the RIG-1-like receptors (RLRs)36,37 which bind to Mitochondrial Antiviral Signaling pro-
tein (MAVS) to elicit an IFN1 response. RLRs also contained several variants which arguably affect the protein 
function - the exceedingly rare start-lost and stop-gain variants (p.Met1? and p.Arg575*) in the DDX58 (a.k.a. 
RIG1), a missense variant (p.Thr438Arg) in the DHX58 and a missense (Met619Val) and stop-gain (p.Glu627*) 
variants present in the IFIH1 (a.k.a. MDA-5) gene of 2 and 7 MS probands, respectively. Some of these have 
been reported previously - The IFIH1 variant p.Glu627* has been associated with lower poly(I:C)-induced IFN1 
production38 and the variant POLR3A p.Gln707Arg with severe varicella zoster virus (VZV) infections39. We 
therefore hypothesize that the variants described in the POLR3-RLR pathway could alter the response to viral 
infections in MS patients, particularly VZV and EBV which are known risk factors for MS40. Besides their impor-
tance in exogenous infections, RLRs also respond to human endogenous retrovirus (HERV)41 sequences whose 
increased expression is associated with MS42 and can also be induced by the infection with EBV43. The IFN1s 
resulting from the activation of RLRs act in an auto- and paracrine fashion to promote clearance of infection, 
inflammasome priming and its inactivation44,45. Crucial to IFN1 pathway are the TYK2 and PTPRC46 genes which 
have been associated with MS in the GWA studies47 and contained several selected variants in the present study. 
IFN1 (intereferon-β) represents the mainstay of MS therapy and its beneficial effects have already been attributed 
to its inhibitory effect on inflammasome activity13,14,45,48. While it is reasonable to assume that MS patients with 
defective POLR3-RLR driven production of interferon-β would respond well to external supplementation, it is 
tempting to speculate that those with affected TYK2 pathway might represent the non-responders.
The highest CADD-scored absent-in-gnomAD variant in the present study was discovered in the RIPK2 gene 
(p.Pro194Ser). The variant was discovered in two MS probands and its extremely high pathogenicity predictions 
are corroborated by the importance of proline residues for RIPK2 protein folding49. Moreover, RIPK2 has reduced 
tolerance to both missense and loss of function variants based on ExAC functional constraint data26. RIPK2 is 
essential for the function of NOD2, with whom it forms a protein complex. While commonly associated with 
response to bacterial infection, NOD2 is increasingly recognized in response to both RNA and DNA viruses50–52. 
By interacting with both the DDX58 and MAVS on the one hand53 and with CARD18, PYCARD and CASP1 on 
the other54, the NOD2/RIPK2 complex is centrally positioned to serve as the integrator of both pathways. This 
is supported by the recent discovery of mutually antagonistic action between the DDX58 and NOD255. The sug-
gested mechanism is based upon the sequestration of DDX58 and NOD2 away from MAVS and RIPK2, which are 
necessary for downstream IFN1 and NF-kB signaling, respectively55 (Fig. 2). RIPK2’s ability to engage in NF-kB 
signaling is also affected by its interaction with CASP1, and hypomorphic genetic variants in the latter have been 
suggested as the cause of febrile episodes56. Interestingly, we discovered an exceedingly rare missense variant 
(CASP1 p.Arg45Ser) at amino acid residue deemed important for this interaction57.
RIPK2 has been shown to dampen inflammasome activation via the regulation of NF-kB-ULK1-SQSTM1 
mediated mitophagy during viral infection58,59. Both autophagy and mitophagy are important negative regulators 
of inflammasome activation22. Interestingly, RIPK2, along with the other members of the RIP kinases family, is 
emerging as an important regulator of the innate and adaptive immune system60. Furthermore, its importance 
in the context of MS has already been demonstrated in both human and animal studies61–63, and clinical stud-
ies on MS patients involving RIPK2 inhibitors64 have already been suggested65. Several other genes involved 
in autophagy contained the variants selected in our study. Both SIRT2 and FOXO3 were involved in inflam-
masome inactivation via autophagy in murine model of nonalcoholic fatty liver66,67, which could be relevant in 
the context of MS as childhood obesity is a recognized MS risk factor68. One possible mechanism could be the 
reduced activity of SIRT2 in high fat diet, resulting in increased trafficking of NLRP3 to the mitochondria and 
subsequent inflammasome activation69. Additionally, SIRT2 also plays a critical role in oligodendrocyte differ-
entiation and the expression of myelin-specific genes70, and deacetylates FOXO3 in response to oxidative stress 
and caloric restriction71. Importantly, MEFV has recently been shown to recruit and organize key components 
of autophagic machinery, including ULK1 and BECN1, and to act as autophagic receptor specific for NLRP1, 
NLRP3 and CASP172.
While all the selected variants were in heterozygous state, several genes carrying the reported variants have 
reduced tolerance to loss of function (RIPK2, CASP1, NLRP3, PTPRC) and missense variation (POLR3A, RIPK2, 
HDAC6, NLRP3, TYK2). Additionally, due to the nature of cooperative inflammasome assembly73, involving 
the interactions of many parts and regulatory proteins, the presence of dominant negative mutations and gene 
dosage sensitivity is likely74,75. As the regulation of both RLRs and inflammasome proteins rely on protein-protein 
interactions via the CARD protein domain, the final output of the signaling complex could be altered by rare 
functional variants affecting these interactions. Such reasoning can potentially explain increased production of 
IL-1β caused by presumably hypomorphic variants in the NLRP1 gene (p.Gly578Ser and p.Asn864fs), which we 
observed in the previously performed functional studies7. All genes from our inflammasome panel which have 
previously been associated with MS in GWA studies2,47 mediate the interferon-β pathway and contained exceed-
ingly rare variants in the present study (TYK2, STAT1, and PTPRC). These genes provide possible examples of 
MS heritability being conveyed by common as well as rare variation within the same genes.
On Fig. 2 we provide a review of inflammasome regulatory pathway and highlight the contribution of two 
pathways in which we found the selected variants. Firstly, while the afferent arm of interferon-β signaling pathway 
has already been associated with MS in GWA studies, we provide preliminary evidence for the importance of its 
efferent arm which leads to interferon-β production in response to infection with EBV and increased expression 
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of HERV. As the EBV infection was recently demonstrated in the brain of 90% of MS patients where it extended 
beyond its canonical host (B-cells) to include astrocytes and microglia as well76, the POLR3-RLR pathway could 
also play a role in cells without clear autoimmune function, including the maintenance of the blood-brain bar-
rier. Secondly, our research corroborates the importance of auto/mito-phagy for inflammasome regulation as we 
highlight several pivotal genes involved in the process – RIPK2, MEFV and SIRT2, FOXO3. The former two have 
already been associated with MS in animal studies and family based rare-variant association studies, respectively, 
and the latter two were implicated in the inflammasome inhibition following high fat diet. As childhood obesity, 
and EBV infection are known risk factors for MS, it is possible that these environmental effects might act in syn-
ergy with genetic predisposition, including in the form of rare coding variants with functional effects described 
within the inflammasome pathway in the present study.
In conclusion, we discovered significantly increased rare variant burden in the inflammasome regulating 
genes of patients with MS, which was most prominent for the exceedingly rare variants that were scored highly by 
the pathogenicity prediction algorithms. These variants support the overall importance of inflammasome and its 
regulation by interferon-β and auto/mito-phagy to the etiology of MS.
Methods
Ethical statement. The study was performed in accordance with the principles stated in the Declaration of 
Helsinki. All participants gave informed written consent to participate in the study. To maintain confidentiality, 
their names were replaced with proband IDs at blood draw. The study was approved by the National Medical 
Ethics Committee (#90/08/12).
participants. The study involved 319 subjects categorized into 3 cohorts. The MSFAM cohort included 86 
MS probands from independent families with multiple affected members (2 or more 1st degree relatives with 
MS). Only a single patient with MS per family was included in the study. The sporadic (MSS) cohort included 89 
MS patients without family history of the disease. The diagnosis of MS was established in accordance with the 
McDonald criteria77. The MS probands originate from Slovenian, Croatian and Serbian population. Ethnically 
matched patients referred to our institute for the diagnosis of suspected Mendelian disease unrelated to MS were 
used as controls (CTRL cohort, n = 144). The cohorts had an average age of 43 and sex ratio of 1.6:1, female to 
male, both of which did not significantly differ between the cohorts. Nineteen probands previously screened 
solely for the NLRP1 variants in our previous publication7 were included in the present MSFAM cohort.
Whole exome sequencing (WES), raw data analysis, and variant annotation. WES of whole 
blood derived DNA was performed on Illumina HiSeq-2000 platform to a standard depth of coverage of 30x. 
Read sequences were aligned to hg19 reference genome using Burrows-Wheeler (BWA) aligner and processed in 
accordance with genome analysis toolkit78 (GATK) best practices (haplotyper-caller in GVCF mode with subse-
quent joint genotyping and variant filtering with VQSR)79. Variant call quality scores assigned by the VQSR are 
reported in the Supplementary Table S1. Various exome capture kits were employed for NGS library preparations 
(Agilent-All-Exon 2/5/6 and Illumina Nextera-Exome) with matching proportions between the cohorts. To fur-
ther diminish the possibility of capture kit derived bias, only universally captured loci were analyzed, and only 
variants that were successfully genotyped in over 95% of probands were retained. A BED file representing the 
overlap of capture kits was generated using Bedtools80 to limit the GATK analysis downstream of alignment step 
to universally captured loci. Additionally, all selected and MS enriched variants had BAM alignment files manu-
ally inspected in the Integrative Genomics Viewer (IGV)81 to further reduce the possibility of false positive variant 
calls. Variants were annotated with snpEff and ANNOVAR within the Variant Tools82 software package. Genome 
Aggregation Database (gnomAD) was employed as the source of variant frequencies in worldwide populations 
(http://gnomad.broadinstitute.org/)26. Combined Annotation–Dependent Depletion (CADD)27 pathogenicity 
prediction algorithm was used to estimate variants’ effect on protein function. CADD-phred is a normalized 
logarithmic scale according to which the variants with scores above 10, 20 and 30 represent the top 10, 1, and 0.1 
percent of highest ranking variants27. Synonymous variants, variants outside coding regions, and variants with 
MAF > 0.05 in gnomAD or within the entire dataset were filtered out, leaving only rare protein-altering variants 
for all further statistical analysis.
Gene panel selection. The panel was assembled out of genes coding for essential inflammasome constit-
uents (NLRP1/3, PYCARD and CASP1) and genes involved in the regulation of its activation28. The latter were 
classified into: a) Genes involved in the priming step leading to transcription of inflammasome constituents, b) 
inhibition of inflammasome assembly by their sequestration, and c) post-translational modification and their 
removal via autophagy or mitophagy. The final gene panel included 62 genes listed in the Table 1.
statistical analysis. Statistical analysis was performed in R statistical environment83. Variants within genes 
from the analyzed panel were aggregated and their burden compared pairwise between MS and control cohorts. 
The significance of the difference in the observed rare variant burden was assessed using R package “SKAT“29. 
“SKATBinary” test in “burden” mode was performed with variant weighting based on gnomAD variant frequency 
data, as described by Madsen et Browning84. For the purpose of variant weighting, the variants absent in gnomAD 
database were assigned a gnomAD MAF of 1 × 10−6 as by extrapolation (variants with 2 and 1 alleles reported in 
gnomAD have MAFs of 8 × 10−6 and 4 × 10−6, respectively). As the SKAT test was performed three times (control 
cohort against both of the MS cohorts and a combined MS cohort) we set a Bonferroni corrected (Alpha: 0.01) 
p-value of 0.003 as the cutoff for statistical significance. Pearson’s Chi-squared test with Yates’ continuity correc-
tion was performed to determine if the variants absent in gnomAD were significantly overrepresented among the 
MS probands compared to the control cohort (using the total number of variants identified in each cohort as the 
background). To establish the MAF and CADD criteria for the selected most likely causative missense variants, 
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the inter-cohort variant burden comparison was performed at 300 equally distributed MAF and CADD-score 
cutoffs below and above which the variants were considered for analysis, respectively (Fig. 1; panels A and B). The 
cutoff of CADD = 20 was chosen as above this value the overrepresentation of variants among the MS probands 
started to grow exponentially. Together with a cutoff at MAF <1 × 10−5 these criteria selected 10% of all identified 
missense variants. All variants with CADD scores available (including stop-gain/loss and splice-site variants) 
qualified among the selected variants using the same criteria. Frame-shift variants could not be assessed by the 
CADD algorithm and were included based only on their MAF. To assess the significance and the specificity of the 
trends depicted in Fig. 1 (panels A and B) to our chosen inflammasome gene panel, linear regression analysis was 
performed, and the slope coefficients were compared to coefficients obtained for 100,000 random gene panels of 
the same size. More information on the method is available in the Supplementary File).
Variants which were discovered in 2 or more MS probands were evaluated to determine whether their multiple 
occurrence in our MS cohorts might be significant, considering their relative scarcity in the general population 
(gnomAD). Fisher exact test was performed comparing the proportions of variant/reference alleles in our MS 
cohorts and the gnomAD database. To eliminate populationally specific variants, the same test was performed 
comparing our control cohort to gnomAD. Variants attaining nominal significance (p < 0.01) in the former but 
not in the latter test were considered “MS enriched”. The same procedure was performed to estimate the signif-
icance of the replication of the two variants reported by Bernales et al.30. As both variants were reported in the 
same proband (in both studies) and have nearly identical frequency reported in the gnomAD, they were consid-
ered as a single haplotype and a single Fisher test comparing the proportions of variant/reference haplotypes in 
MS cohorts from both studies and the gnomAD database was performed.
Data Availability
All data analyzed during this study are included in this published article and its Supplementary Information files. 
All variant datasets generated during the current study are available from the corresponding author on reasonable 
request.
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